GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Phase 1

Completed

Conditions: Solid Tumours

Interventions: Drug: Dabrafenib
Drug: Ipilimumab
Drug: Trametinib

First Posted Date: 2013-01-14

Last Posted Date: 2017-11-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 38

Registration Number: NCT01767454

Locations: 🇺🇸
GSK Investigational Site, Houston, Texas, United States

WEUSKOP5723: Prostate Cancer Study

Completed

Conditions: Prostatic Hyperplasia

Interventions: Other: 5-alpha reductase inhibitors
Other: Alpha-blockers

First Posted Date: 2013-01-14

Last Posted Date: 2016-11-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01767363

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age

Phase 3

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: Meningococcal vaccine GSK134612
Biological: Boostrix®

First Posted Date: 2013-01-14

Last Posted Date: 2017-09-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 692

Registration Number: NCT01767376

Locations: 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of

Pharmacokinetic Study to Compare Two Formulations of Paracetamol

Phase 1

Completed

Conditions: Pain
Fever
Headache Disorders

Interventions: Drug: Paracetamol

First Posted Date: 2013-01-14

Last Posted Date: 2013-01-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT01767428

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea

Phase 4

Completed

Conditions: Meningococcal Disease

Interventions: Biological: MenACWY-CRM (Menveo)

First Posted Date: 2013-01-11

Last Posted Date: 2018-09-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 3948

Registration Number: NCT01766206

Locations: 🇰🇷
GSK Investigational Site, Yangju-si, Gyeonggi-do, Korea, Republic of

WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications
Drug: New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))